Evidence map›Paper›PMID 30258759›Full record

ReviewGlobal spine journal2018

The Challenges of Renal Cell Carcinoma Metastatic to the Spine: A Systematic Review of Survival and Treatment.

C Rory Goodwin, A Karim Ahmed, Christine Boone, Nancy Abu-Bonsrah, Risheng Xu, Niccole Germscheid, Daryl R Fourney, Michelle Clarke, Ilya Laufer, Charles G Fisher and 2 more

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Global spine journal, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 20 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Observational
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 7 institutions in 3 countries.

C Rory GoodwinDuke University Medical Center, Durham, NC, USA.ORCID 0000-0002-6540-2751
A Karim AhmedThe Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Christine BooneThe Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Nancy Abu-BonsrahThe Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Risheng XuThe Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Niccole GermscheidAOSpine International, Davos, Switzerland.
Daryl R FourneyUniversity of Saskatchewan, Saskatoon, Saskatchewan, Canada.
Michelle ClarkeMayo Clinic, Rochester, MN, USA.
Ilya LauferMemorial Sloan-Kettering Cancer Center, New York, NY, USA.
Charles G FisherUniversity of British Columbia, Vancouver, British Columbia, Canada.ORCID 0000-0003-0374-2854
Chetan BettegowdaThe Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Daniel M SciubbaThe Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Johns Hopkins University · USAOSpine · CHDuke Medical Center · USMayo Clinic in Arizona · USMemorial Sloan Kettering Cancer Center · USUniversity of British Columbia · CAUniversity of Saskatchewan · CA

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

STUDY

designSystematic review.

objectivesThe objective of this systematic review was to answer 2 key questions: (1) What is the clinical presentation and probability of symptomatic improvement following treatment for patients with renal cell carcinoma (RCC) of the spine? (2) What is the overall survival of patients diagnosed with spinal metastases from RCC?

methodsA literature review was performed to identify articles that reported on survival, clinical outcomes, and/or prognostic factors in the RCC population with spinal metastases from 1986 to 2016.

resultsForty-eight articles (807 patients) were included. The Fuhrman Nuclear Grade has been significantly associated with survival in previous studies but was underpowered in the current study. The Memorial Sloan-Kettering Cancer Center Score (MSKCC/Motzer) was also underpowered in the current study. From the time of spinal metastasis, the mean and median survival for patients with previously diagnosed primary RCC was 8.75 and 11.7 months, respectively, whereas synchronously diagnosed patients (primary RCC and spinal metastasis) had a mean and median survival of 6.75 and 11 months, respectively. Patients with a "low" (0-8), "intermediate" (9-11), or "high" (12-15) revised Tokuhashi score at initial presentation had a median survival of 5.4, 11.7, and 32.9 months, respectively.

conclusionPatients with either a synchronous or latent diagnosis of RCC survived greater than 6 months from the time of presentation. Initial Furhman grade, Tokuhashi score, and MSKCC/Motzer can be useful tools in informing patient-specific prognosis for those with metastatic RCC of the spine.

Indexed as

kidney cancerradiation therapyrenal cell carcinomaspine metastasissurvivalTokuhashi scoretumor

Identifiers

PMID30258759
PMCPMC6149047
OpenAlexW2770600031

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.